Eton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease Portfolio
Eton Pharmaceuticals' Alkindi Sprinkle is their lead orphan product, addressing a $100M opportunity. Click here to read why ETON stock is a Buy.
United States James Gruber Sean Brynjelsen Global Business Development At Akorn Eton Pharmaceuticals Pharma Sciences Eton
Source: seekingalpha.com